Suppr超能文献

ETA和ETB受体在增生性血管壁中的不同定位。

Different localization of ETA and ETB receptors in the hyperplastic vascular wall.

作者信息

Azuma H, Hamasaki H, Sato J, Isotani E, Obayashi S, Matsubara O

机构信息

Department of Medicinal Chemistry, Tokyo Medical and Dental University, Japan.

出版信息

J Cardiovasc Pharmacol. 1995 May;25(5):802-9. doi: 10.1097/00005344-199505000-00017.

Abstract

We investigated which subtypes of endothelin-1 (ET-1) receptors are involved in the pathogenesis of angioplasty-induced lesion formation in the rabbit carotid artery. Four weeks after removing endothelial cells (EC), we noted a marked intimal hyperplasia. The Bmax values for [125I]ET-1 and [125I]IRL1620 (an agonist for the ETB receptors) bindings were greater in the hyperplastic artery, without changes in Kd values. [125I]ET-1 binding was completely inhibited by unlabeled ET-1 and Ro 46-2005, a mixed-type antagonist for the ETA and ETB receptors, but partially by BQ123, a selective antagonist for ETA receptors, and IRL1620. The [125I]ET-1 binding sites not inhibited with BQ123 were significantly increased in the hyperplastic artery. The binding study suggested the presence of non-ETA/non-ETB receptors. The rank order of the increasing ratio in the density of receptors was ETB > putative non-ETA/non-ETB > total ET-1 receptors > ETA. The histochemical experiments with biotinylated ET-1 at lysine-9 side chain alone or in combination with unlabeled ET-1, BQ123, Ro 46-2005, or IRL1620, showed the ETA receptors to be localized mainly in the media, whereas the ETB receptors localized mainly in the neointima. These results suggest that the increased ET-1 receptors, especially ETB and/or putative non-ETA/non-ETB, are closely related to the occurrence of the intimal hyperplasia after endothelial removal.

摘要

我们研究了内皮素-1(ET-1)受体的哪些亚型参与了兔颈动脉血管成形术诱导的病变形成的发病机制。去除内皮细胞(EC)四周后,我们观察到明显的内膜增生。增生动脉中[125I]ET-1和[125I]IRL1620(ETB受体激动剂)结合的Bmax值更高,而Kd值无变化。未标记的ET-1和Ro 46-2005(ETA和ETB受体的混合型拮抗剂)可完全抑制[125I]ET-1结合,但ETA受体选择性拮抗剂BQ123和IRL1620只能部分抑制。增生动脉中未被BQ123抑制的[125I]ET-1结合位点显著增加。结合研究提示存在非ETA/非ETB受体。受体密度增加比例的排序为ETB>推定的非ETA/非ETB>总ET-1受体>ETA。用生物素化的赖氨酸-9侧链ET-1单独或与未标记的ET-1、BQ123、Ro 46-2005或IRL1620联合进行的组织化学实验表明,ETA受体主要定位于中膜,而ETB受体主要定位于新生内膜。这些结果表明,ET-1受体增加,尤其是ETB和/或推定的非ETA/非ETB,与内皮去除后内膜增生的发生密切相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验